摘要
目的探讨富马酸伏诺拉生联合枸橼酸莫沙必利治疗胃食管反流病(GERD)患者的临床效果。方法将61例GERD患者随机分为伏诺拉生组(n=31)和兰索拉唑组(n=30)。给予伏诺拉生组患者富马酸伏诺拉生联合枸橼酸莫沙必利治疗,给予兰索拉唑组患者兰索拉唑联合枸橼酸莫沙必利治疗,两组患者均治疗4周。比较两组患者的疗效、安全性,以及治疗前后的胃肠激素、炎症因子水平。结果治疗后,伏诺拉生组患者的症状缓解率高于兰索拉唑组(P<0.05)。治疗后,两组患者的血清胃动素、胃泌素水平较治疗前升高,血清胆囊收缩素(CCK)、血管活性肠肽(VIP)、白细胞介素(IL)-1β、IL-6、IL-8、5-羟色胺水平较治疗前降低,且伏诺拉生组患者的血清胃动素、胃泌素水平高于兰索拉唑组,血清CCK、VIP、IL-1β、IL-6、IL-8、5-羟色胺水平低于兰索拉唑组(P<0.05)。治疗期间,两组患者的总药物不良反应发生率差异无统计学意义(P>0.05)。结论富马酸伏诺拉生联合枸橼酸莫沙必利治疗GERD疗效显著,可明显改善患者的胃肠激素水平,降低炎症因子水平,且安全性良好。
Objective To explore the clinical effect of Vonoprazan Fumarate Tablets combined with Mosapride Citrate for the treatment of patients with gastroesophageal reflux disease(GERD).Methods A total of 61 GERD patients were randomly divided into vonoprazan group(n=31)or lansoprazole group(n=30).Patients in the vonoprazan group received Vonoprazan Fumarate Tablets combined with Mosapride Citrate for treatment,whereas the lansoprazole group received lansoprazole combined with Mosapride Citrate for treatment.Both groups receive a 4-week treatment.The efficacy,safety,and pre-and post-treatment gastrointestinal hormones and inflammatory factors levels were compared between the two groups.Results After treatment,the vonoprazan group exhibited a higher remission rate of syndromes as compared with the lansoprazole group(P<0.05).Both groups interpreted elevated levels of serum motilin and gastrin,whereas decreased levels of serum cholecystokinin(CCK),vasoactive intestinal peptide(VIP),interleukin(IL)-1β,IL-6,IL-8,and 5-hydroxytryptamine after treatment.The vonoprazan group depicted higher levels of serum motilin and gastrin,while lower levels of serum CCK,VIP,IL-1β,IL-6,IL-8,and 5-hydroxytryptamine after treatment as compared with the lansoprazole group(P<0.05).There was no statistically significant difference in the total incidence rate of adverse reactions of drugs between the two groups(P>0.05).Conclusion Vonoprazan Fumarate Tablets combined with Mosapride Citrate for the treatment of GERD exerts significant efficacy,which can prominently ameliorate patients'gastrointestinal hormones levels,and decrease inflammatory factors levels,exerting favorable safety.
作者
曾莉蓉
潘庆华
易艳芳
石昊
周海艳
ZENG Lirong;PAN Qinghua;YI Yanfang;SHI Hao;ZHOU Haiyan(Department of Spleen and Stomach Diseases,the Central Hospital of Enshi Tujia and Miao Autonomous Prefecture,Enshi 445000,Hubei,China)
出处
《广西医学》
2025年第6期827-831,共5页
Guangxi Medical Journal
基金
湖北省卫生健康委员会科研项目(WJ2021F091)。
关键词
胃食管反流病
富马酸伏诺拉生
枸橼酸莫沙必利
兰索拉唑
疗效
安全性
Gastroesophageal reflux disease
Vonoprazan Fumarate Tablets
Mosapride Citrate
Lansoprazole
Efficacy
Safety
